Dominick Angiolillo, MD, PhD, a professor of medicine and director of cardiovascular research at the University of Florida College of Medicine – Jacksonville, remains one of the world’s most influential researchers, according to a recent list released by Clarivate.
Clarivate, formerly part of Thomson Reuters, tracks the number of times scientists are cited in science and social science journals worldwide. Its Highly Cited Researchers list for 2020 accounts for citations over an 11-year span, from the start of 2009 through 2019, and features the scientists who rank in the top 1% of their respective field.
Angiolillo, who appears in the clinical medicine category, has published more than 500 peer-reviewed manuscripts and has been cited nearly 39,000 times throughout his career. He has now made the Highly Cited Researchers list in all seven years of its existence.
“In 2020, fewer than 6,200, or about 0.1%, of the world's researchers, in 21 research fields and across multiple fields, have earned this exclusive distinction,” Clarivate wrote in a letter to Angiolillo, who is the only UF faculty member recognized in clinical medicine this year. “You are among this elite group recognized for your exceptional research influence.”
As Angiolillo reflects on the honor, he is quick to express much appreciation for those who have assisted him throughout his career.
“I would like to thank my research team and colleagues, who have all been fantastic over the nearly 20 years I have been at UF Health,” Angiolillo said. “I also want to thank my family for their support and all of the patients who have agreed to partake in our research activities.”
Over the past several years, Angiolillo’s research has focused on strategies to personalize care for patients with various cardiac conditions, with the goal of improving efficacy and safety. Most recently, activities include an ongoing study to determine if blood thinners can help prevent blood clots that can cause strokes, pulmonary embolisms and deep vein thrombosis in people who have tested positive for COVID-19.
“Through our research, we hope the approaches implemented to personalize care at our specialized practice can become more broadly available,” Angiolillo said. “Our desire is for outcomes of patients with cardiac conditions to be positively affected on a larger scale.”
Dominick J. Angiolillo, MD, PhD, FACC
Medical Director, Cardiovascular Research Program; Program Director, Interventional Cardiology Fellowship Program; Associate Program Director, Cardiovascular Disease Fellowship